MYC and metabolic dysfunction-associated steatotic liver disease: To verify whether the expression of MYC was indeed decreased in NAFLD patients, we adopted another four datasets, including GSE164760, GSE37031, GSE48452, and GSE63067 with 186 samples in all to validate the results further, which contained 125 NAFLD patients and 61 healthy controls, merged and batch-adjusted as shown in Figure 7A.